|
Synonyms: SG-001 | SG001
enlonstobart is an approved drug
Compound class:
Antibody
Comment: Enlonstobart (SG001) is a fully humanised anti-PD-1 (PDCD1) monoclonal antibody. It was developed to treat advanced solid tumours by blocking the inhibitory the PD-1/PD-L1/L2 immune checkpoint.
|
| No information available. |
Summary of Clinical Use  |
| The Chinese drug regulator (NMPA) approved enlonstobart (Enshuxing®) in June 2024, to treat recurrent or metastatic programmed cell death ligand 1 (PD-L1)-positive cervical cancer that is insensitive to platinum-containing chemotherapy [2]. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT04886700 | Study of the SG001 Injection for Patients With Relapsed or Metastatic Uterine Cervical Cancer | Phase 2 Interventional | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 1 | |
| NCT03852823 | Study of Recombinant Human Anti-PD-1 Monoclonal Antibody in Patients With Advanced Tumours | Phase 1 Interventional | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 3 | |
